ESMO 2022 | Influence of sidedness on prognosis and treatment in mCRC

Chiara Cremolini, MD, PhD, University of Pisa, Pisa, Italy, discusses the impact of sidedness on the prognosis and treatment of patients with metastatic colorectal cancer (mCRC). Right-sided tumors are more aggressive and patients experience a poorer prognosis. Patients with right-sided tumors are also associated with increased molecular alterations driving intrinsic resistance to anti-EGFR monoclonal antibodies. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.